<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and therapy-related <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) are now recognized as <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> that occur a few years after chemotherapy for primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> or <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> is usually <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and sometimes is preceded by a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0006721'>Acute lymphoblastic leukemia</z:hpo> (ALL) as a secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> is quite rare, and secondary T-cell ALL after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is even rarer </plain></SENT>
<SENT sid="3" pm="."><plain>We report a case of a 56-year-old woman who developed T-cell ALL after a 3-year remission of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (M2) </plain></SENT>
<SENT sid="4" pm="."><plain>We thought that this case would be extremely valuable for studying the etiology and biological characteristics of T-cell ALL as a secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>